smartdyelivery

est. 2014

Our Vision

" Magical spheres " for the therapy of diseases

Our Vision

„We must learn to create magical spheres that ... only hit the pathogens.”

Paul Ehrlich 1854-1915

With tailor-made nanocarriers, we will set new standards for the targeted, efficient and low-risk use of active pharmaceutical ingredients and other highly potent substances for medical and life science applications.

NEWS

January 29, 2021

POLYTARGET PRESENT THEIR NEW IMAGE FILM: Within the framework of the Collaborative Research Center »PolyTarget« of the Deutschen Forschungsgemeinschaft, the co-founders of SmartDyeLivery GmbH (Prof. Dr Ulrich S. Schubert, Prof. Dr med. Michael Bauer and Dr Anja Träger) are developing innovative pharmaceutical polymers and nanoparticles for use in nanomedicine. The image film shows the research work in which the SmartDyeLivery GmbH is a strategic partner.

DECEMBER 07, 2020

JOINT PUBLICATION WITH RESEARCHERS OF THE UNIVERSITY OF JENA AWARDED: The high-ranking publication in the scientific journal Nanoscale, published jointly with scientists from the Institute of Organic Chemistry and Macromolecular Chemistry (IOMC) on October 8, 2020, has been added to the Topic Collection 2020 Nanoscale HOT Article Collection.

October 14, 2020

SUCCESSFUL MULTI-MILLION FINANCING ROUND: SmartDyeLivery is pleased to announce the successful completion of its most recent financing round. In addition to bm-t beteiligungsmanagement thüringen gmbh (bm|t), which increased its lead investment, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT), a group of business angels was also convinced. The investment will be used to finance important development steps for the specific therapy of septic liver failure - up to the first application in humans. Read the complete press release here.

DEVELOPMENT OF NEW THERAPY OPTIONS

In a first field of application we focus on the targeted transport of active substances in liver cells. We are thus creating a therapeutic option for the treatment of patients with septic cholestasis with the aim of reducing the extremely high mortality rate caused by this complication.